GeneHealth - Your precision medicine

Osteogenesis Imperfecta Type 10

Disease Details

Family Health Simplified

Buy Membership

Description: Osteogenesis imperfecta type 10 is a severe form of a genetic disorder characterized by fragile bones that break easily, often with little or no apparent cause.
Type: Osteogenesis imperfecta type 10 is inherited in an autosomal recessive pattern.
Signs And Symptoms: Osteogenesis imperfecta type 10 (OI type X) is a rare genetic disorder characterized by:

**Signs and Symptoms:**

1. **Bone Fragility**: Individuals have brittle bones that break easily, often with little or no apparent cause.
2. **Short Stature**: Reduced growth can lead to shorter-than-average height.
3. **Blue Sclerae**: The whites of the eyes may appear blue or gray.
4. **Hearing Loss**: Some affected individuals may experience hearing loss.
5. **Dentinogenesis Imperfecta**: Teeth may be discolored, translucent, and prone to wear and breakage.
6. **Joint Laxity**: Loose joints and hypermobility can be present.
7. **Skeletal Deformities**: This may include bowing of long bones, scoliosis, or other deformities.
8. **Respiratory Issues**: In severe cases, lung complications can occur due to rib cage deformities.

The severity of these symptoms can vary widely among individuals with OI type X. Proper diagnosis and management by healthcare professionals are crucial for improving quality of life.
Prognosis: Osteogenesis imperfecta type 10 (OI type X) is a rare form of osteogenesis imperfecta, a genetic disorder characterized by fragile bones that break easily. The prognosis for individuals with OI type X can vary widely depending on the severity of the condition. In general, people with mild forms may have a relatively normal lifespan and quality of life with proper medical management, whereas those with severe forms may experience significant challenges, including frequent fractures, severe deformities, and potential complications that could impact overall health and longevity. There are no specific data provided under your request for "nan" (assumed to be 'not applicable' or 'not available') in terms of prognosis for this particular type.
Onset: Osteogenesis imperfecta type 10 (OI type X) typically presents onset during infancy to early childhood. The specific age at which symptoms appear may vary among affected individuals.
Prevalence: Osteogenesis imperfecta type 10 (OI type X) is an extremely rare form of osteogenesis imperfecta. Due to its rarity, specific prevalence data is not well-documented. Cases are typically identified based on clinical features and genetic testing, but comprehensive prevalence estimates are lacking.
Epidemiology: Osteogenesis imperfecta type 10 is an extremely rare subtype of osteogenesis imperfecta (OI), a genetic disorder characterized by brittle bones that are highly susceptible to fractures. Due to its rarity, specific epidemiological data for type 10 is not well-documented or as thoroughly studied as more common types of OI. Generally, OI affects approximately 1 in 15,000 to 20,000 live births, but type 10 constitutes a very small fraction of these cases. Data on its prevalence and incidence are largely unavailable or not well-established.
Intractability: Osteogenesis imperfecta type 10 (OI type 10) is considered a severe form of osteogenesis imperfecta, a genetic disorder characterized by fragile bones that break easily. While there are no cures currently available, management focuses on improving quality of life through medication, physical therapy, orthopedic interventions, and other supportive measures. The disease is typically intractable in the sense that it cannot be completely cured, but symptoms and complications can often be managed to some extent with appropriate medical care.
Disease Severity: Osteogenesis imperfecta type 10 is a severe form of osteogenesis imperfecta. It is characterized by very fragile bones that fracture easily, frequent bone deformities, and often a significant impact on growth and development. This type is due to mutations in the SERPINH1 gene.
Healthcare Professionals: Disease Ontology ID - DOID:0110346
Pathophysiology: Osteogenesis imperfecta type 10 (OI type 10) is a rare genetic disorder characterized by mutations in the SERPINF1 gene. This gene encodes pigment epithelium-derived factor (PEDF), a protein involved in bone formation and maintenance. The pathophysiology of OI type 10 primarily involves defective collagen production and abnormalities in bone mineralization:

1. Impaired Collagen Synthesis: The mutations in SERPINF1 lead to deficiencies in PEDF, which is crucial for the proper formation of the bone matrix and collagen structure. Collagen is a vital component of connective tissue, contributing to bone strength and flexibility.

2. Defective Bone Mineralization: PEDF also plays a role in regulating bone mineralization by influencing the differentiation and activity of osteoblasts (cells that form new bone) and osteoclasts (cells that resorb bone). Deficiency in PEDF disrupts these processes, resulting in poorly mineralized and structurally weak bones.

These disruptions result in the clinical manifestations of OI type 10, including bone fragility, frequent fractures, skeletal deformities, and growth deficiencies.
Carrier Status: Osteogenesis imperfecta type 10 is an autosomal recessive disorder, implying that carriers (heterozygous individuals) typically do not exhibit symptoms of the disease. Carriers have one mutated copy and one normal copy of the gene BGLAP involved. Both parents must be carriers for a child to be affected. Hence, carrier status is relevant for genetic counseling and family planning.
Mechanism: Osteogenesis imperfecta type 10 (OI type 10) is caused by mutations in the SERPINF1 gene, which encodes for the protein PEDF (pigment epithelium-derived factor). This protein is involved in bone formation and maintenance.

**Mechanism:**
OI type 10 is characterized by brittle bones that are prone to fractures and other connective tissue abnormalities.

**Molecular Mechanisms:**
1. The SERPINF1 mutations lead to a deficiency or dysfunction of the PEDF protein.
2. PEDF plays a role in regulating bone remodeling by inhibiting osteoclast activity (cells that break down bone tissue) and promoting osteoblast activity (cells that form bone).
3. A deficiency in PEDF disrupts this balance, leading to excessive bone resorption and inadequate bone formation.
4. This imbalance results in the weakened bone matrix characteristic of osteogenesis imperfecta.

These molecular disruptions ultimately lead to the clinical manifestations seen in OI type 10, including frequent fractures, bone deformities, and other connective tissue problems.
Treatment: Osteogenesis imperfecta type 10 is a rare genetic disorder characterized by brittle bones and frequent fractures. Treatment focuses on managing symptoms and improving quality of life. This typically includes:

1. **Bisphosphonates**: These medications can help increase bone density and reduce fracture risk.
2. **Physical Therapy**: Strengthening muscles around bones to improve mobility and reduce fracture risk.
3. **Orthopedic Surgery**: Procedures such as rodding surgeries to insert metal rods into long bones to stabilize and strengthen them.
4. **Pain Management**: Medications and therapies to manage chronic pain.
5. **Genetic Counseling**: Offering guidance and support to affected individuals and their families.

Note: The specifics of treatment can vary based on individual cases and advancements in medical research.
Compassionate Use Treatment: Osteogenesis imperfecta type 10 is a rare genetic disorder characterized by fragile bones and other connective tissue issues. This specific subtype is caused by mutations in the SERPINH1 gene.

Given the complexities and rarity, standard treatments involve managing symptoms and improving quality of life through conventional methods like bisphosphonates, physical therapy, and surgical interventions to correct bone deformities. However, for compassionate use or experimental treatments, the following approaches are considered:

1. **Stem Cell Therapy**: Experimental studies have explored the use of mesenchymal stem cell transplantation to improve bone density and reduce fracture rates. Clinical trials are ongoing to better understand efficacy and safety.

2. **Gene Therapy**: Research is ongoing to explore the potential of gene editing technologies, like CRISPR-Cas9, to correct the underlying genetic mutation. This is still in the experimental stage and not yet available as a mainstream treatment.

3. **Bone Morphogenetic Proteins (BMPs)**: These proteins are being studied for their potential to enhance bone repair and regeneration. While promising in animal models, more research and clinical trials are needed for use in humans.

4. **Growth Hormone Therapy**: Some investigations are examining the use of growth hormone to improve growth and bone density in patients. This is considered experimental for osteogenesis imperfecta.

5. **Denosumab**: Although primarily used for osteoporosis, research is exploring its off-label potential to reduce bone resorption and increase bone mass in osteogenesis imperfecta patients.

Access to these treatments typically requires enrollment in clinical trials or obtaining compassionate use approval through regulatory agencies, as they are not standard treatments for the disease.
Lifestyle Recommendations: For osteogenesis imperfecta type 10, lifestyle recommendations include:

1. **Regular Monitoring**: Regular follow-ups with a healthcare provider to monitor bone health and growth.
2. **Safe Physical Activity**: Engage in low-impact exercises such as swimming or walking to maintain muscle strength and bone health while minimizing fracture risk.
3. **Balanced Diet**: Ensure a diet rich in calcium and vitamin D to support bone health.
4. **Medication Adherence**: Use prescribed medications and supplements as directed by a healthcare provider.
5. **Bone Health Management**: Follow any bone health management plan, which may include bisphosphonates to increase bone density.
6. **Adaptive Equipment**: Utilize orthotic devices, braces, or wheelchairs as needed for mobility and to prevent fractures.
7. **Fall Prevention**: Implement fall prevention strategies in the home, like removing trip hazards and using non-slip mats.
8. **Mental Health Support**: Seek support for emotional well-being, such as counseling or support groups, to cope with the challenges of living with a chronic condition.
9. **Education and Awareness**: Educate family members, caregivers, and educators about the condition to ensure a supportive environment.

Always consult with a healthcare provider for personalized recommendations and guidance.
Medication: There are no specific medications tailored exclusively for Osteogenesis Imperfecta Type 10. Management typically includes measures aimed at improving bone strength and managing symptoms. Bisphosphonates, such as pamidronate or zoledronic acid, are commonly used to enhance bone density and reduce fracture risk. Additionally, other treatments may involve physical therapy, surgical interventions for fractures or deformities, and calcium and vitamin D supplementation to support bone health. For personalized medical treatment, consulting a healthcare professional is essential.
Repurposable Drugs: For osteogenesis imperfecta type 10, there is very limited specific information regarding repurposable drugs directly targeting this subtype due to its rarity and specific genetic cause. However, general approaches for managing osteogenesis imperfecta (OI), including potential repurposable drugs, might include:

1. **Bisphosphonates**: Commonly used to increase bone density and reduce fracture rates in OI patients.
2. **Teriparatide (Forteo)**: A recombinant form of parathyroid hormone that has shown some promise in improving bone density.
3. **Denosumab (Prolia)**: A monoclonal antibody against RANKL, possibly useful for increasing bone density by inhibiting bone resorption.
4. **Sclerostin inhibitors**: These are in the early stage of research but may promote bone formation.

These drugs are generally used for broader categories of OI and their suitability for type 10 should be evaluated by healthcare professionals based on individual patient needs and potential benefits versus risks.

For detailed medical advice and treatment options, consulting a healthcare provider with expertise in genetic disorders and bone diseases is crucial.
Metabolites: Osteogenesis imperfecta type 10 is a rare genetic disorder characterized by fragile bones that break easily. Metabolites are not typically the primary focus in diagnosing or understanding this condition. Osteogenesis imperfecta type 10 is caused by mutations in the SERPINH1 gene, which affects the production and quality of collagen, a key structural protein in bones.
Nutraceuticals: There is currently no established or specific nutraceutical treatment for osteogenesis imperfecta type 10. Treatment typically focuses on managing symptoms and improving quality of life through physical therapy, medications to strengthen bones, and sometimes surgical interventions. Nutritional support, including adequate intake of calcium and vitamin D, is generally recommended for bone health. Always consult with a healthcare provider for personalized medical advice.
Peptides: Osteogenesis imperfecta type 10 (OI type 10) is a rare genetic disorder affecting connective tissue integrity, primarily characterized by bones that break easily. It is caused by mutations in the SERPINF1 gene, which is involved in the production of a protein essential for bone strength and structure. Peptides and nanotechnology-based therapies are areas of ongoing research and potential treatment development for various genetic disorders, including OI. However, specific peptides or nanotechnology applications for OI type 10 have not yet been established as standard treatment.